Critical Medicines Act, AI Tops HEOR Trends, NICE Advice ROI

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: the Critical Medicines Act operational framework, AI topping ISPOR trends, and NICE advice timeline data. Let's get into it.

SaraThe Critical Medicines Act provisional agreement puts EMA's Executive Steering Group on Shortages and Safety front and center for supply chain vulnerability assessments across over 200 active substances on the Union critical medicines list. This isn't just regulatory housekeeping.

MarcusAgreed, but I'm skeptical about execution. EMA's MSSG conducting vulnerability assessments across 200+ substances sounds comprehensive on paper, but the methodology for these assessments isn't defined. How do you quantify supply chain vulnerability in a way that's actionable for market access?

SaraThat's exactly why this matters commercially. If EMA flags certain therapeutic areas as high-vulnerability, it creates a de facto prioritization signal for HTA bodies. Companies with robust supply chains in critical categories could see accelerated pathways.

MarcusOr it creates another layer of regulatory burden. We've seen how JCA scientific advice slots got capped because demand exceeded capacity. Now EMA's supposed to assess vulnerabilities across major therapeutic categories while maintaining standard approval timelines?

SaraThe political agreement came together in May for a reason. Member states are feeling supply pressure, and they're willing to give EMA expanded authority. The question isn't whether this creates burden—it's whether companies can turn compliance into competitive advantage.

MarcusFair point, but the devil's in the implementation details we don't have yet.

MarcusISPOR's 2026-2027 trends report puts AI at number one, up from third position. Real-world evidence slides to second, value-based healthcare enters at third. This reflects where the evidence generation conversation is heading.

SaraI'm not buying the AI hype at number one. Yes, it's generating buzz at conferences, but where's the regulatory uptake? EMA and NICE aren't restructuring assessment frameworks around AI-generated evidence. This feels like ISPOR chasing headlines.

MarcusYou're missing the methodological shift. AI isn't about replacing traditional evidence—it's about processing complex datasets that were previously unanalyzable. The FIBRONEER trial program for nerandomilast was the largest in IPF and PPF to date. That scale requires computational approaches.

SaraBut that's data management, not evidence strategy. When HTA bodies evaluate nerandomilast, they're looking at clinical endpoints, not whether the sponsor used machine learning for trial logistics. AI ranking above RWE suggests ISPOR's priorities are disconnected from HTA reality.

MarcusI disagree. AI is enabling new forms of evidence synthesis that HTA bodies will have to grapple with. Systematic reviews, indirect treatment comparisons, health economic modeling—all of these are being transformed by computational approaches. The ranking reflects where the field is going, not where it is today.

SaraThen why is value-based healthcare suddenly at number three as a new trend? VBC has been discussed for years. If AI is truly transformative, it should be enabling better VBC implementation, not competing with it for attention.

MarcusThat actually supports the AI argument—these trends are interconnected, and AI is the enabling technology.

SaraNICE's analysis shows scientific advice cuts appraisal timelines by nearly three months—312 days versus 400 days from marketing authorization to guidance publication. That's a significant ROI across 230 technology appraisal documents.

MarcusThe sample size is solid with 51 technologies receiving NICE advice, but I want to see the therapeutic area breakdown. Complex oncology assessments with multiple indications might see bigger timeline benefits than straightforward single-indication submissions.

SaraTrue, but the commercial implications are clear regardless of therapeutic area. Three months earlier market access translates directly to revenue, especially for high-value treatments. The MHRA-NICE aligned pathway launching with 25% lower fees and 2,300 webinar registrations shows demand.

MarcusThe fee reduction is encouraging, but I'm concerned about capacity constraints. If scientific advice becomes standard practice, NICE will face the same bottleneck issues we've seen with EMA. Quality of advice might suffer as volume increases.

SaraThat's a scaling problem, not a strategic one. The 312 versus 400 day difference represents systematic process improvement, not just individual company benefit. NICE is demonstrating that upfront engagement improves overall system efficiency.

MarcusPossibly, but the companies using scientific advice might be self-selecting—those with stronger dossiers and more experienced teams. The timeline benefit could reflect submission quality rather than advice effectiveness.

SaraEven if there's selection bias, the directional impact is clear. Earlier engagement improves outcomes.

MarcusThe MHRA-NICE aligned pathway going operational represents genuine regulatory innovation. Single entry point, one advice meeting, one report, one payment—that's streamlined compared to parallel processes.

SaraIt's a start, but the real test is whether this model scales to other European markets. If Germany or France develop similar aligned pathways, we could see fragmented approaches that complicate rather than simplify market access.

MarcusThe 40% fee reduction for SMEs suggests they're serious about access, not just efficiency. That could drive innovation in digital health technologies where smaller companies often lead.

SaraAgreed on the SME angle, but the proof will be in assessment consistency. Aligned pathways only work if MHRA and NICE maintain coherent standards. One bad experience with divergent recommendations could undermine the entire framework.

MarcusFair concern. The operational details matter more than the structural elegance.

SaraThis week shows regulation catching up to market realities—supply chain vulnerabilities, computational approaches to evidence, and streamlined pathways. The question is execution speed versus market need.

MarcusExecution remains the key variable. Ambitious frameworks mean nothing without methodological rigor and operational capacity. Back tomorrow on Access Brief. Show notes at outcomes-analytica.no.